SCHEMBL20202564

SCHEMBL20202564

Cc1ccc(C(C2CC2)n2nc(COCc3ccccc3)c(C(N)=O)c2N)cc1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.55
HCRTR2 O43614 10/20 0.36
RET P07949 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
NPY1R P25929 1/20 0.34
MAOB P27338 1/20 0.34
ADORA2A P29274 1/20 0.34
RECQL P46063 1/20 0.34
NPY2R P49146 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
GHSR Q92847 3/20 0.34
MAPK1 P28482 1/20 0.34
HPGD P15428 1/20 0.34
DHFR P00374 1/20 0.34
BTK Q06187 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18282725 0.88 PDE2A (0.59) PDE2AMAOBGHSR
SCHEMBL18283117 0.85 PDE2A (0.69) PDE2ARETKDM4EALDH1A1MAPT
SCHEMBL20202563 0.83 PDE2A (0.60) PDE2ARETKDM4EALDH1A1MAPT
SCHEMBL20202565 0.82 PDE2A (0.54) PDE2ARETKDM4EALDH1A1MAPT
SCHEMBL18283165 0.80 PDE2A (0.65) PDE2ARETGHSRDHFRBTK
SCHEMBL20202568 0.79 PDE2A (0.45) PDE2ARET
SCHEMBL20581431 0.77 PDE2A (0.74) PDE2ARETKDM4EALDH1A1GHSR
SCHEMBL24211353 0.76 PDE2A (0.65) PDE2ARETGHSRMAPK1
SCHEMBL18290678 0.76 PDE2A (0.46) PDE2AMAOB
SCHEMBL20202573 0.76 MAPK1 (0.51) PDE2AKDM4EALDH1A1MAPTNPY1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS MERCK SHARP & DOHME CORP. (US) 2018-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148453-A1 DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS PDE12, PDE2A, PDE4D PDE2A 2/4885HCRTR2 1225/4885RET 1879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.